Introduction to MOD-4023 (Long-Acting hGH)
MOD-4023 is a long-acting recombinant human growth hormone (hGH) analog developed to reduce injection frequency compared to traditional daily growth hormone therapy. In later-stage development, it has been referred to as somatrogon.
Conventional hGH treatment requires daily subcutaneous injections, which may impact adherence in pediatric populations. As a result, long-acting formulations like MOD-4023 were designed to extend half-life and allow once-weekly dosing while maintaining biological activity.
Phase 2 Study Overview
The Phase 2 clinical trial evaluating MOD-4023 focused on children diagnosed with growth hormone deficiency (GHD). The study assessed:
- Safety and tolerability
- Annualized height velocity
- IGF-1 serum levels
- Dose-response relationships
- Pharmacokinetics and pharmacodynamics
Participants received varying weekly doses to determine optimal therapeutic ranges and evaluate comparative performance against daily recombinant hGH therapy.
Efficacy Findings
Annualized Height Velocity
One of the primary endpoints in the Phase 2 study was annualized height velocity. Results indicated that weekly MOD-4023 dosing produced growth responses comparable to those observed with daily hGH in studied groups.
Dose-dependent increases in height velocity were reported, supporting continued development into later-phase trials.
IGF-1 Stability
IGF-1 levels serve as a biomarker for growth hormone activity. The study demonstrated that weekly administration maintained IGF-1 concentrations within target ranges across dosing intervals.
Stable IGF-1 levels are essential when evaluating the consistency and effectiveness of long-acting growth hormone analogs.
Safety and Tolerability
Safety monitoring in the Phase 2 trial included assessment of adverse events, laboratory parameters, and injection site reactions.
Reported observations included:
- Injection site discomfort
- Headache
- Mild fluid retention
- Transient laboratory changes
No unexpected safety signals were identified during the study duration. However, as with all growth hormone therapies, long-term safety evaluation remains critical.
Clinical Significance of Long-Acting hGH
Reducing injection frequency from daily to weekly may improve treatment adherence in pediatric patients with GHD. Improved compliance can play an important role in maintaining consistent therapeutic exposure and supporting growth outcomes.
Long-acting growth hormone analogs continue to be an active area of research within pediatric endocrinology.
Ongoing Research Considerations
While Phase 2 data were encouraging, further investigation in larger Phase 3 trials is necessary to confirm:
- Long-term safety
- Immunogenicity profiles
- Sustained growth outcomes
- Comparative metabolic effects
Extended follow-up is essential to fully understand the long-term implications of weekly growth hormone therapy.
Conclusion
The Safety and Efficacy Phase 2 Study of Long-Acting hGH (MOD-4023) demonstrated promising growth velocity outcomes and manageable safety observations in children with growth hormone deficiency.
Although results supported continued clinical development, comprehensive long-term data are required to establish full safety and therapeutic positioning within pediatric endocrinology.
⚠️ Research Use Only (RUO) Warning
This article is provided strictly for informational and scientific discussion purposes.
Any reference to MOD-4023 or related compounds is intended for laboratory and research use only.
Not for human or veterinary use. Not for diagnostic or therapeutic application.
Products referenced are not intended to diagnose, treat, cure, or prevent any disease.
⚠️ Research Use Only (RUO) Disclaimer – HealthLab Peptides
All products referenced or sold by HealthLab Peptides are intended strictly for laboratory research purposes only.
Not for human use. Not for veterinary use. Not for diagnostic, therapeutic, cosmetic, or food use.
These compounds are not drugs, supplements, or medications and have not been evaluated by the FDA. Products sold by HealthLab Peptides are not intended to diagnose, treat, cure, or prevent any disease.
By purchasing from HealthLab Peptides, customers agree that:
- Products are used solely for lawful research purposes.
- Products will not be used for human or animal consumption.
- Products will not be used in clinical or household applications.
- The buyer assumes full responsibility for proper handling and compliance with all applicable laws.
HealthLab Peptides makes no claims regarding medical benefits or outcomes. All information provided on this website is for educational and scientific discussion purposes only.
